Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target

Clinical Cancer Research

Volumn 22, Issue 15, 2016, Pages 3831-3840

  Yakirevich, Evgeny ^a   Resnick, Murray B ^a   Mangray, Shamlal ^a   Wheeler, Michael ^a   Jackson, Cynthia L ^a   Lombardo, Kara A ^a   Lee, Jeeyun ^b   Kim, Kyoung Mee ^b   Gill, Anthony J ^c   Wang, Kai ^d   Gowen, Kyle ^d   Sun, James ^d   Miller, Vincent A ^d   Stephens, Philip J ^d   Ali, Siraj M ^d   Ross, Jeffrey S ^d,e   Safran, Howard ^a  

^a BROWN UNIVERSITY   (United States)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c UNIVERSITY OF SYDNEY   (Australia)

^d FOUNDATION MEDICINE   (United States)

^e ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERITINIB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANAPLASTIC LYMPHOMA KINASE; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; ROS1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ALK GENE; ARTICLE; ASCENDING COLON; C2ORF44 GENE; CAD GENE; CANCER GENETICS; CANCER RESISTANCE; CANCER SIZE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; COLON BIOPSY; COLORECTAL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DISEASE ACTIVITY; EML4 GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE; GENE IDENTIFICATION; GENE REARRANGEMENT; GENE TARGETING; GENETIC SCREENING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MAPRE3 GENE; MICROSATELLITE INSTABILITY; MULTIPLE CYCLE TREATMENT; PHENOTYPE; PPP1R21 GENE; PRIORITY JOURNAL; PRKAP1B GENE; RARE DISEASE; RETROSPECTIVE STUDY; SENPF GENE; SKIN METASTASIS; STRN GENE; VERY ELDERLY; ADENOCARCINOMA; BIOPSY; COLORECTAL TUMOR; DISEASE EXACERBATION; GENETICS; GENOMICS; HIGH THROUGHPUT SEQUENCING; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BIOPSY; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MOLECULAR TARGETED THERAPY; ONCOGENE PROTEINS, FUSION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; TREATMENT OUTCOME;

EID: 84979992202     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-3000     Document Type: Article

References (40)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29.
2. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 2014;64:252-71.
3. Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 2014;371:1609-18.
4. Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Mahoney MR, O'Neil BH, et al. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol 2014;32:5s.
5. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330-7.
6. Stransky N, Cerami E, Schalm S, Kim JL, Lengauer C. The landscape of kinase fusions in cancer. Nat Commun 2014;5:4846.
7. Medico E, Russo M, Picco G, Cancelliere C, Valtorta E, Corti G, et al. The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets. Nat Commun 2015;6:7002.
8. Mariño-Enríquez A, Dal Cin P. ALK as a paradigm of oncogenic promiscuity: different mechanisms of activation and different fusion partners drive tumors of different lineages. Cancer Genet 2013;206:357-73.
9. Yoshihara K, Wang Q, Torres-Garcia W, Zheng S, Vegesna R, Kim H, et al. The landscape and therapeutic relevance of cancer-associated transcript fusions. Oncogene 2015;34:4845-54.
10. Shaw AT, Hsu PP, Awad MM, Engelman JA. Tyrosine kinase gene rearrangements in epithelial malignancies. Nat Rev Cancer 2013;13: 772-87.
11. Lin E, Li L, Guan Y, Soriano R, Sanchez Rivers C, Mohan S, et al. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res 2009;7:1466-76.
12. Lipson D, Capelletti M, Yelensky R, Otto G, Parker A, Jarosz M, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 2012;18:382-4.
13. Aisner DL, Nguyen TT, Paskulin DD, Le AT, Haney J, Schulte N, et al. ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers. Mol Cancer Res 2014;12:111-8.
14. Houang M, Toon CW, Clarkson A, Sioson L, de Silva K, Watson N, et al. ALK and ROS1 overexpression is very rare in colorectal adenocarcinoma. Appl Immunohistochem Mol Morphol 2015;23:134-8
15. Lee J, Kim HC, Hong JY, Wang K, Kim SY, Jang J, et al. Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening. Oncotarget 2015;6:24320-32.
16. Katayama R, Lovly CM, Shaw AT. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine. Clin Cancer Res 2015;21:2227-35.
17. Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94.
18. Massarelli E, Papadimitrakopoulou V. Ceritinib for the treatment of latestage (metastatic) non-small cell lung cancer. Clin Cancer Res 2015;21: 670-4.
19. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
20. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013;31: 1023-1031.
21. Hall MJ, Gowen K, Sanford EM, Ali SM, Kaczmar J, Miller VA, et al. Evaluation of microsatellite instability (MSI) status in gastrointestinal (GI) tumor samples tested with comprehensive genomic profiling (CGP). J Clin Oncol 2016;34.
22. Hamilton SR, Bosman FT, Boffetta P, Ilyas M, Morreau H, Nakamura S-I, et al. Carcinoma of the colon and rectum. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO classification of tumours of the digestive system . 4th edition. Lyon (France): IARC Press; 2010. p. 134-46.
23. Smith G, Bounds R, Wolf H, Steele RJ, Carey FA, Wolf CR. Activating K-Ras mutations outwith hotspot' codons in sporadic colorectal tumours -implications for personalised cancer medicine. Br J Cancer 2010;102: 693-703.
24. Mano H. ALKoma: a cancer subtype with a shared target. Cancer Discov 2012;2:495-502.
25. Schulte JH, Bachmann HS, Brockmeyer B, Depreter K, Oberthür A, Ackermann S, et al. High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma. Clin Cancer Res 2011;17:5082-92.
26. Bresler SC, Weiser DA, Huwe PJ, Park JH, Krytska K, Ryles H, et al. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell 2014;26:682-94.
27. Seshagiri S, Stawiski EW, Durinck S, Modrusan Z, Storm EE, Conboy CB, et al. Recurrent R-spondin fusions in colon cancer. Nature 2012;488:660-4.
28. Brannon AR, Vakiani E, Sylvester BE, Scott SN, McDermott G, Shah RH, et al. Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biol 2014;15:454.
29. Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014;370: 1189-97.
30. Patel B, Yu Y, Majumdar AP. IGF-1R: A therapeutic target for colon cancer stem-like cells. J Clin Oncol 2010;28.
31. Garcia-Carbonero R, Agullo-Ortuño MT, Lopez-Rios F, Diaz-Garcia CV, Cortijo A, Cortes-Funes H, et al. Evaluation on the IGF-IR Inhibitor CP-751,871, alone and in combination with paclitaxel in lung and colon cell lines. J Clin Oncol 2009;27.
32. Van Cutsem E, Eng C, Nowara E, Swieboda-Sadlej A, Tebbutt NC, Mitchell E, et al. Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer. Clin Cancer Res 2014;20:4240-50.
33. Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Maru D, et al. Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J Clin Oncol 2015;33:4032-8.
34. Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, et al. Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer. J Clin Oncol 2015;33:4023-31.
35. Sartore-Bianchi A, Ardini E, Bosotti R, Amatu A, Valtorta E, Somaschini A, et al. Sensitivity to entrectinib associated with a novel LMNA-NTRK1 gene fusion in metastatic colorectal cancer. J Natl Cancer Inst 2015;108; djv306.
36. Le Rolle AF, Klempner SJ, Garrett CR, Seery T, Sanford EM, Balasubramanian S, et al. Identification and characterization of RET fusions in advanced colorectal cancer. Oncotarget 2015;6:28929-37.
37. Kelly LM, Barila G, Liu P, Evdokimova VN, Trivedi S, Panebianco F, et al. Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. Proc Natl Acad Sci U S A 2014;111:4233-8.
38. Pérot G, Soubeyran I, Ribeiro A, Bonhomme B, Savagner F, Boutet-Bouzamondo N, et al. Identification of a recurrent STRN/ALK fusion in thyroid carcinomas. PLoS One 2014;9:e87170.
39. Roth AD, Delorenzi M, Tejpar S, Yan P, Klingbiel D, Fiocca R, et al. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J Natl Cancer Inst 2012;104:1635-46.
40. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509-20.